RANI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.7M
-0.1%
1.7M
+0.0%
1.7M
+16.9%
1.5M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
1.7M
-0.1%
1.7M
+0.0%
1.7M
+16.9%
1.5M
0
Operating Expenses
10.9M
+3.7%
10.5M
+4.9%
10.0M
+0.5%
10.0M
+37.7%
7.3M
R&D
6.0M
+20.0%
5.0M
-2.8%
5.2M
+5.1%
4.9M
+52.4%
3.2M
SG&A
4.9M
-11.1%
5.5M
+13.0%
4.9M
-4.0%
5.1M
+26.0%
4.0M
Operating Income
-9223000
-4.5%
-8828000
-5.9%
-8339000
+2.3%
-8535000
-17.6%
-7257000
EBITDA
-9100000
-4.9%
-8676000
-6.1%
-8178000
+2.0%
-8349000
-18.7%
-7034000
Net Income
-8806000
-4.6%
-8421000
-5.1%
-8015000
+11.7%
-9074000
-14.7%
-7914000
EPS (Basic)
$-0.04
+0.0%
$-0.04
+0.0%
$-0.04
+42.9%
$-0.07
+41.7%
$-0.12
EPS (Diluted)
$-0.04
+0.0%
$-0.04
+0.0%
$-0.04
+42.9%
$-0.07
+41.7%
$-0.12
Shares (Diluted)
199.0M
+6.3%
187.2M
+4.0%
180.0M
+21.5%
148.1M
+218.9%
46.4M
Rani Therapeutics (RANI) — Financials